Related Experiment Video
Updated: Sep 15, 2025
10:59
Production of Apolipoprotein C-III Knockout Rabbits using Zinc Finger Nucleases
Published on: November 18, 2013
18.3K
Targeting Triglycerides: The Rise of Apolipoprotein C3 and Angiopoietin-Like Protein 3 Inhibitors
Taha Mansoor1, Vijay Nambi2,3, Sachin Parikh4
1Department of Internal Medicine, Western Michigan University Homer Stryker M.D. School of Medicine, 1000 Oakland Dr, Kalamazoo, MI, 49008, USA. taha.mansoor@wmed.edu.
Summary
New treatments targeting apolipoprotein C3 (APOC3) and angiopoietin-like protein 3 (ANGPTL3) show promise for managing hypertriglyceridemia. Novel agents are in development, with some already approved for specific conditions.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Lipid Metabolism
Background:
- Hypertriglyceridemia is linked to atherosclerotic cardiovascular disease (ASCVD) risk.
- Elevated triglycerides (TG) indicate remnant cholesterol, a causal factor in ASCVD.
- Limited effective treatments exist for high TG levels.
Purpose of the Study:
- To review novel pharmacotherapy options for hypertriglyceridemia.
- To highlight promising therapeutic targets, including APOC3 and ANGPTL3.
- To provide updated insights into the development of new hypertriglyceridemia treatments.
Main Methods:
- Comprehensive review of current scientific literature.
- Analysis of novel agents targeting APOC3 and ANGPTL3 pathways.
- Examination of clinical development status for new TG-lowering medications.
Main Results:
- Several novel agents (olezarsen, plozasiran, zodasiran) are under development.
- Olezarsen received approval in 2024 for familial chylomicronemia syndrome.
- APOC3 and ANGPTL3 represent key targets for novel pharmacotherapies.
Conclusions:
- Novel therapeutic strategies targeting APOC3 and ANGPTL3 offer significant potential for managing hypertriglyceridemia.
- Ongoing research and development are expanding treatment options for patients with elevated TG.
- These advancements may lead to improved outcomes in preventing ASCVD.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
878
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
878
01:26Atherosclerosis III: Management
40
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
40
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
651
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
651
01:23Dipeptidyl Peptidase 4 Inhibitors
262
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
262
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
257
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
257
01:27Peripheral Artery Disease III: Interprofessional Care
30
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
30